Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Poster and Presentation
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Poster and Presentation
2020 ADA Poster
The Anti-diabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes.
Read More
2020 ADA Poster
Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)
Read More
2019 ADA Poster
Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study.
Read More
2019 ADA Poster
Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care
Read More
2018 ADA Poster
Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator, Dorzagliatin (HMS5552) 12 Weeks Treatment in T2D Patients in China
Read More
2017 June
Clinical Proof of Concept (POC) of A Novel Dual-acting Glucokinase Activator (GKA) Achieved: HMS5552 improved glycemic control in T2DM Patients
Read More
<<
<
1
2
3
4
5
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x
Venice-Macao-marketing@3187y.com
Sun-City-Entertainment-service@bfsc1986.com
博彩网站
中国娱乐网电视剧频道
New-Portuguese-gambling-marketing@zxunweb.com
澳门新葡京博彩
伊菲股份
威尼斯人官网
皇冠现金网
中国航空集团公司
The-Crown-Casino-website-help@shoppersdeli.com
人文百科
美高梅
国美电器网上商城活动专区
房客网
重庆人文科技学院
Crown-betting-contactus@fxsxhd.com
利物浦FC
为你辩护网
Venetian-Online-sales@walkerclass.com
中国交通论坛
中央一台在线直播
17173暗黑3专区
友基科技
榕树下
保定欣欣旅游网
虾米音乐网
精品女性网
BT好搜
当当电器城
中影人艺考
站点地图
品漉高尔夫官网
天津医科大学